Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunovant (IMVT) EPS (Weighted Average and Diluted) (2020 - 2026)

Immunovant filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.61 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 19.74% to -$0.61 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.68 through Dec 2025, down 2.29% year-over-year, with the annual reading at -$2.73 for FY2025, 45.21% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.61 in Q4 2025 for Immunovant, up from -$0.73 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.28 in Q1 2021 and bottomed at -$0.76 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.5, with a median of -$0.47 recorded in 2023.
  • The largest annual shift saw EPS (Weighted Average and Diluted) grew 26.53% in 2023 before it tumbled 111.11% in 2024.
  • Immunovant's EPS (Weighted Average and Diluted) stood at -$0.36 in 2021, then plummeted by 36.11% to -$0.49 in 2022, then rose by 26.53% to -$0.36 in 2023, then tumbled by 111.11% to -$0.76 in 2024, then rose by 19.74% to -$0.61 in 2025.
  • Per Business Quant, the three most recent readings for IMVT's EPS (Weighted Average and Diluted) are -$0.61 (Q4 2025), -$0.73 (Q3 2025), and -$0.71 (Q2 2025).